primary end point with ivabradine1
cardiovascular death with ivabradine
inhibitor, β-blocker, mineralocorticoi receptor antagonist.
17% P=0.0109 REDUCTION in all-cause death with ivabradine
39% P=0.0006 REDUCTION in death from heart failure
1. Böhm M, et al. Clin Res Cardiol. 2013;102(1):11-22.you want to know more …
on the impact of elevated heart rate on the primary outcomes
The greater the heart rate reduction (≥10 bpm or heart rate <60 bpm at 28 days), the lower the primary end point event rate whatever the baseline heart rate.1